(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 468.79% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.15%.
Roivant Sciences's revenue in 2026 is $7,532,000.On average, 15 Wall Street analysts forecast ROIV's revenue for 2027 to be $39,297,983,631, with the lowest ROIV revenue forecast at $9,843,818,048, and the highest ROIV revenue forecast at $69,321,339,750. On average, 15 Wall Street analysts forecast ROIV's revenue for 2028 to be $289,817,663,308, with the lowest ROIV revenue forecast at $84,237,310,009, and the highest ROIV revenue forecast at $483,320,775,797.
In 2029, ROIV is forecast to generate $1,126,823,903,400 in revenue, with the lowest revenue forecast at $723,767,661,030 and the highest revenue forecast at $1,656,286,673,395.